REPLIGEN CORPORATION Reports Fourth Quarter FY2022 Earnings Results on February 22 2023.
March 7, 2023
Earnings report
REPLIGEN CORPORATION ($NASDAQ:RGEN) reported their financial results for the fourth quarter of FY2022, which ended on December 31 2022, on February 22 2023. The company experienced a 67.4% increase in total revenue year over year, reaching USD 48.7 million. Reported net income was slightly up, by 0.1%, to USD 186.8 million. This growth was driven by strong performance in their products, which were mainly sold to other businesses and health care organizations engaged in bioprocessing, as well as in the pharmaceutical and regenerative medicine markets. REPLIGEN CORPORATION attributed the growth to an increase in sales of their purified proteins and monoclonal antibodies.
These are both vital components that are used in drug development processes and for therapeutic treatments. The company’s financial performance for the fourth quarter of FY2022 was a testament to their dedication to driving long-term growth and profitability. This strong performance is likely to continue in the coming quarters based on the positive outlook for their products and the market share they are expected to capture. Furthermore, the company recently announced multiple new initiatives that are expected to further increase their revenues in the near future.
Stock Price
REPLIGEN stock opened at $179.5 and closed at $170.0, signifying a 4.5% decrease from the previous closing price of 178.0. The earnings report revealed a year-on-year revenue decrease of 3%, along with a net income decrease of 1%. While the company saw improvement in some of its core metrics, the earnings report overall seemed to have disappointed investors. As a result, there has been a significant selloff in REPLIGEN’s stock, with investors showing concern over the company’s financial health moving forward. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Repligen Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 801.54 | 185.96 | 19.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Repligen Corporation. More…
| Operations | Investing | Financing |
| 172.08 | -233.24 | -13.34 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Repligen Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.52k | 613.96 | 34.39 |
Key Ratios Snapshot
Some of the financial key ratios for Repligen Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 43.7% | 75.8% | 27.5% |
| FCF Margin | ROE | ROA |
| 4.8% | 7.4% | 5.5% |
Analysis
GoodWhale recently completed an analysis of REPLIGEN CORPORATION and found that the company is a risky investment. Our Risk Rating suggests that, based on financial and business aspects, the REPLIGEN CORPORATION is a high risk investment. Upon further examination, we discovered three potential risks in REPLIGEN CORPORATION’s income sheet, balance sheet, and cashflow statement. As a registered GoodWhale user, you can check out our findings to get more information about REPLIGEN CORPORATION’s risk factors. More…
Peers
The company’s products include proteins and antibodies for the treatment of cancer, central nervous system disorders, and infectious diseases. ReGen Biologics Inc, Tecan Group AG, Stevanato Group SPA are all competitors in the market for developing and commercializing therapeutics.
– ReGen Biologics Inc ($OTCPK:RGBOQ)
Regen Biologics, Inc. is a biotechnology company, which focuses on the development, commercialization, and marketing of products in the orthopedic regenerative medicine field. The company’s products include collagen-based scaffolds for use in orthopedic and sports medicine indications. It operates in the United States, Europe, and Asia. The company was founded by David A. Jay and Stephen J. Sacks in 1997 and is headquartered in Laguna Niguel, CA.
– Tecan Group AG ($OTCPK:TCHBF)
Tecan Group AG is a Swiss-based manufacturer of laboratory instruments and solutions for the life sciences sector. The company has a market cap of 4.54B as of December 2020 and a Return on Equity of 6.13%. Tecan Group AG’s products are used in academic and commercial research laboratories, as well as in clinical diagnostic laboratories. The company’s instruments are used for a variety of applications, including drug discovery and development, biopharmaceutical production, food safety testing, and environmental monitoring.
– Stevanato Group SPA ($NYSE:STVN)
Stevanato Group is a leading provider of integrated solutions for the pharmaceutical and biotech industry. The Group offers a complete range of services, from design and development to manufacturing and packaging of finished products. The Group’s products are used in a wide range of therapeutic areas, including cancer, immunology, infectious diseases and neurology.
Summary
Total revenue increased by 67.4% year over year to USD 48.7 million and reported net income was up 0.1% to USD 186.8 million. Despite these positive results, the stock market did not respond positively on the news and the stock price dropped on the same day. Overall, these results suggest a potential buying opportunity for investors interested in the stock, with strong revenue growth and consistent net income.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
